Search results for: 'diseas visualization market size'

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...

The infectious disease IVD market in Indonesian presents diversified growth potential for different tiers of participants. Domestic participants stand to gain from the growth momentum in the lower-end market, whereas foreign leading manufacturers dominate the higher-end market. This research service analyses the infectious disease IVD market and p...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

This research service evaluates the global autoimmune disease diagnostics markets from 2009 to 2018. The market includes two segments, which include analysis for the markets for localized autoimmune disease diagnostic tests and for the systemic autoimmune disease diagnostic tests. This research service offers a discussion of the key market drivers ...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast by segment, drivers and restraints, and technology trends, along with the competitive factors and strategies, and key companies to watch. The global market is primarily driven by the high prevalen...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...